Treatment-Resistant Depression treatment in Eatontown, New Jersey

Treatment-resistant depression (TRD) is depression that hasn't responded enough to standard first-line treatment. The most-used clinical definition: failure of two or more antidepressant trials, at an adequate therapeutic dose, for adequate duration (typically 6 to 8 weeks each). TRD is not a separate disease from major depressive disorder. It's a clinical category that describes where standard treatment has gone so far.

About 30% of people with major depression meet criteria for TRD at some point, per NIH data. The number is higher in patients with severe depression or with significant comorbidity (anxiety disorders, substance use, chronic medical illness, trauma history). TRD doesn't mean treatment is impossible. It means the next steps are different from "try another SSRI."

The framing matters. The STAR*D study — the largest depression treatment study to date — found that remission rates drop with each successive medication trial: about 1 in 3 patients reach remission with the first trial, fewer with the second, fewer still with the third and fourth. The clinical implication: after two failed adequate trials, the highest-yield next move is usually a different class of treatment, not a different SSRI. That includes augmentation with another medication class, switching to a fundamentally different mechanism, or moving to a non-medication intervention like TMS.

We don't diagnose in copy on a website. The criteria below help you frame your own treatment history. The actual TRD evaluation happens in a psychiatric visit — usually 60 to 90 minutes — and includes a careful review of every medication you've tried, the doses, the durations, and what happened with each.

Many patients labeled as treatment-resistant turn out to have had inadequate trials, not true non-response. This is one of the most-missed clinical details in outpatient psychiatry. An "adequate trial" requires three things, all three.

Adequate dose. Antidepressants have a therapeutic dose range. Many patients are stopped or labeled as non-responders before reaching the upper end of that range. Sertraline at 50 mg is a starting dose, not a therapeutic dose for many patients with moderate-to-severe depression. Same for the other SSRIs and SNRIs. A first move when reviewing a "failed" trial is often to confirm what the actual top dose was.

Adequate duration. Antidepressants take 4 to 8 weeks to reach full effect at adequate dose. Many trials get stopped at 3 weeks because of intolerable side effects or because the patient feels like nothing is happening. Sometimes that's the right call. Sometimes the trial just hadn't had enough time.

Adequate adherence. Taking 70% of doses isn't the same as taking 95%. Many depressive episodes themselves degrade adherence — forgetting, fatigue, ambivalence about treatment. A reasonable conversation about adherence isn't an accusation; it's a clinical fact-finding step.

Why this matters. Before treating depression as TRD with TMS, esketamine, or augmentation strategies, the standard of care is to confirm the prior trials were actually adequate. Sometimes the next move is going back to a previous medication and giving it the dose and duration it didn't get the first time. Sometimes that's not the answer. Either way, the question is asked.

We do this review at the first TRD-focused visit. If you have records or can recall doses and durations, bring them. If you can't, that's also fine — we work with what's available.

Patients with TRD often arrive at our clinic having been depressed long enough that the depression has changed shape. Some specific patterns we see:

Anhedonia (loss of pleasure) becomes the dominant symptom in many long-standing depressions, sometimes more than sadness itself. The capacity to feel anything — positive or negative — fades. Some patients describe this as "going through the motions" or "watching their life from outside."

Cognitive symptoms (poor concentration, memory issues, slowed thinking, difficulty making decisions) often become prominent after months or years of unrelieved depression. These can persist even when mood symptoms partially respond to medication.

Sleep and energy disturbance is often persistent. Hypersomnia (sleeping too much) is common in long-standing depression; for some patients, the sleep itself feels unrefreshing regardless of duration.

Functional erosion is the lived consequence. The job, relationships, household, and self-care that you used to maintain may all feel harder than they "should." That is not a character problem.

Suicidal ideation is more common in TRD than in first-episode depression. It can be passive (thoughts that life isn't worth continuing) or active (thoughts of suicide with method or plan). Either deserves clinical attention. If you're having active suicidal thoughts, call or text 988 right now. The Suicide and Crisis Lifeline is free and 24/7. New Jersey residents can also reach the NJ Hopeline at 1-855-654-6735. Our clinic is outpatient; an active suicidal crisis requires the emergency room or a higher level of care.

The list below collects symptoms patients commonly bring to a TRD-focused visit. It's not a diagnostic tool. If several resonate, that's information worth bringing to a clinician.

The next move after two failed antidepressant trials depends on what's been tried, the severity of the current presentation, and your priorities. There is no single "next medication" for TRD. There are several paths, and the right one depends on the case.

Augmentation. Adding a second medication to an existing antidepressant that produced partial response. Three augmentation strategies have the strongest evidence:

• Lithium. Used for decades as an antidepressant augmenter. Evidence is robust, particularly for patients who had partial response to an SSRI. Requires blood level monitoring.
• T3 thyroid hormone (liothyronine). Less commonly known but well-evidenced. Augments antidepressant response in patients with normal baseline thyroid function. Generally well-tolerated.
• Atypical antipsychotics at low dose. Aripiprazole (Abilify), quetiapine (Seroquel XR), and brexpiprazole (Rexulti) are FDA-approved for adjunctive use with antidepressants. The trade-off is metabolic side effects (weight gain, glucose, lipids) requiring monitoring.

Switching. Moving to a different antidepressant class. Often the first move is from SSRI to SNRI (or vice versa). Less commonly used: switching to bupropion (different mechanism — dopamine and norepinephrine), or to clomipramine (a tricyclic with strong evidence in some TRD presentations).

Combination antidepressants. Some patients respond to two antidepressants from different classes used together — for example, an SSRI plus bupropion, or an SNRI plus mirtazapine. The "California rocket fuel" combination (venlafaxine plus mirtazapine) has clinical evidence in some TRD presentations.

TMS — transcranial magnetic stimulation. FDA-approved for TRD since 2008. Non-invasive, in-office, no anesthesia, no systemic side effects. Daily 20- to 40-minute sessions, five days a week, for 4 to 6 weeks. Response rates in TRD: roughly 50 to 60% across pooled trials, with about 1 in 3 patients achieving full remission. We deliver TMS at our Eatontown office. See our TMS service page for what to expect.

Esketamine (Spravato). FDA-approved 2019 for TRD. Delivered as a nasal spray in a clinical setting under REMS-program monitoring (2-hour observation after each dose, twice weekly initially, then tapered). Effective for many TRD patients. We do not deliver esketamine ourselves — we refer to specialty providers in the region when it's the right fit.

ECT — electroconvulsive therapy. Still the most effective treatment for severe TRD by response rate (60–80% response, higher remission rates than TMS). ECT requires brief anesthesia and is delivered in a hospital outpatient setting. The cultural stigma around ECT doesn't match the evidence. For severe, prolonged TRD with significant suicidality or treatment urgency, ECT is sometimes the right call. We refer when clinically indicated.

Therapy. When you've tried medication for years without enough response, dedicated focused therapy sometimes adds what medication alone hasn't. CBT, behavioral activation, and IPT all have evidence in TRD specifically. For patients who haven't been in active therapy alongside medication, this is sometimes the first move rather than the last.

TMS is the in-clinic TRD intervention we deliver directly. It's the most-used non-medication option for TRD across U.S. outpatient practice and is increasingly the first move after two failed antidepressant trials, especially when augmentation strategies haven't worked or aren't tolerated.

How TMS works. Magnetic pulses delivered through a coil placed against the scalp stimulate the dorsolateral prefrontal cortex — a brain region that's chronically underactive in depression. The magnetic pulses pass through the skull without invasive procedures and induce small electrical currents in the targeted region. The mechanism is well-characterized; the long-term effects involve changes in connectivity between brain regions.

The protocol. Standard TMS for depression is delivered Monday through Friday for 4 to 6 weeks — typically 30 to 36 sessions. Each session runs 20 to 40 minutes. You're awake during treatment, can drive yourself to and from the office, and can return to work the same day.

Response rates. Across pooled trials, roughly 50 to 60% of TRD patients achieve clinically meaningful response (a 50% reduction in standardized depression score). About 1 in 3 reach full remission. These numbers are honest. TMS is not universally effective. It is, for the right patient, transformative.

Side effects. Mild and typically transient. The most common: scalp discomfort during the session (especially the first week as the dose calibrates) and mild headache after sessions. Both usually resolve within the first week. Unlike many psychiatric medications, TMS has no systemic side effects — no weight change, no sexual dysfunction, no GI symptoms.

Contraindications. The main one: metallic implants near the head (some pacemakers, some cochlear implants, some surgical clips). Active seizure disorder is a contraindication for standard TMS protocols. We screen for these at the initial consultation.

Insurance coverage. Most commercial plans, Medicare, NJ FamilyCare, and Tricare cover TMS for TRD with prior authorization. The required documentation usually includes: current diagnosis, history of two or more adequate antidepressant trials, current symptom-rating scores, and a treatment plan. We handle the prior-auth submission. Approval typically takes 3 to 5 business days. We don't begin TMS until coverage is confirmed in writing.

What to bring to the TMS consultation. Records of prior medication trials if you have them. A list of medications you've tried with doses and approximate durations. Any prior psychiatric records that document the diagnosis. If you don't have records, that's okay — we work with what's available and request what we can.

For the broader TMS service detail — including the specific brain target, the difference between standard rTMS and the newer SAINT/iTBS protocols, and our equipment — see our TMS service page.

Patients researching TRD often come across three additional options: ketamine, ECT, and pharmacogenomic testing. Honest framing on each:

Ketamine and esketamine (Spravato). FDA-approved esketamine is delivered as a nasal spray in REMS-monitored clinical settings — twice weekly initially, with 2-hour observation after each dose, then tapered. Response rates in TRD are similar to TMS (50-60% response, 30-40% remission). Side effects include dissociation during the session (intentional and time-limited), sometimes transient blood pressure elevation, and rare bladder symptoms with long-term use. We do not deliver esketamine at our clinic. We refer to specialty providers in the region. Off-label IV ketamine is also offered at some specialty clinics; this is a separate clinical pathway from FDA-approved esketamine.

ECT — electroconvulsive therapy. ECT is the most effective treatment for severe TRD by efficacy data (60-80% response, higher remission rates than any other option). It involves brief anesthesia and a controlled, monitored seizure delivered through scalp electrodes — a precise medical procedure, not the dramatic version in old films. Modern ECT has cognitive side effects (typically transient memory issues around the treatment period) but is generally well-tolerated. The cultural stigma around ECT doesn't match the clinical evidence. We refer to hospital-based ECT programs for patients with severe TRD when clinically indicated.

Pharmacogenomic testing (GeneSight, Genomind, others). Commercial tests that analyze genetic variants affecting medication metabolism and response. The marketing implies a personalized "right medication" answer; the actual evidence is mixed. Some studies show modest benefit; others find no clinically meaningful improvement compared to standard prescribing. We discuss pharmacogenomic testing with patients who ask but don't routinely require it. Insurance coverage is inconsistent. If you've already done one and have results, bring them — we'll incorporate them. If you haven't, the standard of care doesn't require one.

The point: more options exist than "another SSRI" or "TMS or nothing." We talk through which path fits your specific situation at the first TRD-focused visit.

Many patients with TRD have been taking medication for years and have not been in active therapy alongside it. When they start, the gains are sometimes substantial — even when the medication picture stays the same. Therapy doesn't replace medication for TRD, and medication doesn't replace therapy. The strongest evidence is for combined treatment.

CBT for chronic depression has specific protocols (CBASP — Cognitive Behavioral Analysis System of Psychotherapy is the most-evidenced) that work differently from CBT for first-episode depression. The work focuses on patterns that have calcified over years of unrelieved depression — patterns of disconnection, self-criticism, and relationship withdrawal that have become "just how things are."

Behavioral activation can help patients who've lost the motivation to do things they used to find meaningful. It's structured, action-oriented, and works alongside medication.

Interpersonal therapy (IPT) and acceptance and commitment therapy (ACT) have evidence in chronic and recurrent depression. They're often a good fit for patients whose depression has been complicated by relationship loss, role transitions, or the cumulative effect of prolonged illness on identity.

Trauma-focused therapy is sometimes the missing piece. A meaningful share of TRD patients have unprocessed trauma that no antidepressant or augmentation strategy will fully address. EMDR, prolonged exposure, or trauma-focused CBT can change the trajectory in ways medication can't. See our PTSD page for the broader trauma framework.

We frequently see patients who come for a TMS consultation, end up doing TMS, and also start active therapy at the same time. The combination outperforms either alone for many TRD presentations. Insurance generally covers therapy and TMS in parallel when the indication is clear.

Honest answer: it depends on what's worked, what hasn't, what level of intervention you're starting, and your specific clinical picture. Some markers:

For augmentation strategies. A new augmentation typically takes 6 to 8 weeks at adequate dose to know whether it's working. Lithium and atypical antipsychotic augmentation evaluations work on this timeline.

For switching antidepressants. Cross-tapering plus the new medication's onset means roughly 8 to 12 weeks to know whether the new medication is producing meaningful response.

For TMS. Standard 4-6 week treatment course. Many patients notice some change in week 2 or 3; full evaluation happens at the end of the course. Re-treatment is sometimes possible if symptoms return.

For combined approaches. When TMS, augmentation, and active therapy are all in play, the active treatment phase typically runs 3 to 6 months. Maintenance after that is individualized.

For severe TRD with ECT. ECT response usually appears within the first 6 to 12 sessions (delivered 2-3 times weekly). The acute course typically runs 6 to 12 sessions, with some patients continuing maintenance ECT at lower frequency.

Maintenance and relapse prevention. TRD has higher recurrence rates than first-episode depression. We build relapse-prevention skills into the final phase of any successful treatment so you have tools when symptoms try to return. Some patients stay on maintenance medication long-term. Some do periodic booster TMS sessions. The maintenance plan depends on what worked acutely.

We don't promise that any specific treatment will work for you. We do promise to be honest about response rates, careful about reviewing what's been tried, and persistent about the next step. TRD is a chronic-condition framing, not a terminal one. More options remain after every step.